Brain mitochondria as a primary target in the development of treatment strategies for Alzheimer disease

International Journal of Biochemistry and Cell Biology

Volumn 41, Issue 10, 2009, Pages 1989-2004

  Aliev, Gjumrakch ^a,b   Palacios, Hector H ^a   Walrafen, Brianna ^a   Lipsitt, Amanda E ^c   Obrenovich, Mark E ^d   Morales, Ludis ^b  

^a The University of Texas at San Antonio   (United States)

^b PONTIFICIA UNIVERSIDAD JAVERIANA   (Colombia)

^c University of Texas Health Science Center at San Antonio   (United States)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer disease; Brain hypoperfusion; Mitochondrial failure; Neurodegeneration; Oxidative stress

Indexed keywords

AMYLOID BETA PROTEIN; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; APOLIPOPROTEIN E4; CARNITINE; LEVACECARNINE; LIPID; MITOCHONDRIAL DNA; REACTIVE OXYGEN METABOLITE;

AGING; ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; BLOOD BRAIN BARRIER; BRAIN ATHEROSCLEROSIS; BRAIN BLOOD FLOW; BRAIN DAMAGE; BRAIN MITOCHONDRION; BRAIN PERFUSION; CEREBROVASCULAR DISEASE; DEGENERATIVE DISEASE; DEMENTIA; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFICACY; GENE DELETION; HUMAN; LIPID PEROXIDATION; NEUROPATHOLOGY; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; REVIEW; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; TREATMENT PLANNING; VASCULAR ENDOTHELIUM;

AGING; ALZHEIMER DISEASE; ANIMALS; BRAIN; HUMANS; MITOCHONDRIA; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 68949152521     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2009.03.015     Document Type: Review

References (160)

1. Acuna-Castroviejo D., Martin M., et al. Melatonin, mitochondria, and cellular bioenergetics. J Pineal Res 30 2 (2001) 65-74
2. Al-Abdulla N.A., and Martin L.J. Apoptosis of retrogradely degenerating neurons occurs in association with the accumulation of perikaryal mitochondria and oxidative damage to the nucleus. Am J Pathol 153 2 (1998) 447-456
3. Aliev G. Is non-genetic Alzheimer's disease a vascular disorder with neurodegenerative consequences?. J Alzheimers Dis 4 6 (2002) 513-516
4. Aliev G., and Burnstock G. Watanabe rabbits with heritable hypercholesterolaemia: a model of atherosclerosis. Histol Histopathol 13 3 (1998) 797-817
5. Aliev G., Castellani R.J., et al. Pathobiology of familial hypercholesterolemic atherosclerosis. J Submicrosc Cytol Pathol 36 3-4 (2004) 225-240
6. Aliev G., Cirillo R., et al. Changes in vessel ultrastructure during ischemia and reperfusion of rabbit hindlimb: implications for therapeutic intervention. Microvasc Res 46 1 (1993) 65-76
7. Aliev G., Gasimov E., et al. Atherosclerotic lesions and mitochondria DNA deletions in brain microvessels: implication in the pathogenesis of Alzheimer's disease. Vasc Health Risk Manag 4 3 (2008) 721-730
8. Aliev G., Liu J., et al. Neuronal mitochondrial amelioration by feeding acetyl-L-carnitine and lipoic acid to aged rats. J Cell Mol Med 13 2 (2009) 320-333 Epub ahead print, 2008
9. Aliev, G., Liu, J., et al. (in press). Preventing cognitive decline in elderly demented/depressed patients and in ApoE4 mouse as a model of human AD by feeding Acetyl-L-Carnitine and Lipoic Acid. In: International conference on Alzheimer's disease; July 11-16, 2009. Vienna, Austria. Control/Tracking Number: 09-A-729-ALZ.
10. Aliev G., Obrenovich M.E., et al. Antioxidant therapy in Alzheimer's disease: theory and practice. Mini Rev Med Chem 8 13 (2008) 1395-1406
11. Aliev G., Seyidova D., et al. Atherosclerotic lesions and mitochondria DNA deletions in brain microvessels as a central target for the development of human AD and AD-like pathology in aged transgenic mice. Ann N Y Acad Sci 977 (2002) 45-64
12. Aliev G., Shenk J.C., et al. Stem cell niches as clinical targets: the future of anti-ischemic therapy?. Nat Clin Pract Cardiovasc Med 5 9 (2008) 590-591
13. Aliev G., Shi J., et al. Neuronal mitochondrial abnormalities in yeast artificial chromosome (YAC) transgenic mice overexpressing amyloid precursor protein (APP). Soc Neurosci Abs Book 30 26 (2000)
14. Aliev G., Smith M.A., et al. Mitochondria as a primary target for vascular hypoperfusion and oxidative stress in Alzheimer's disease. Mitochondrion 4 5-6 (2004) 649-663
15. Aliev G., Smith M.A., et al. Role of vascular hypoperfusion-induced oxidative stress and mitochondria failure in the pathogenesis of Azheimer disease. Neurotox Res 5 7 (2003) 491-504
16. Aliev G., Smith M.A., et al. The role of oxidative stress in the pathophysiology of cerebrovascular lesions in Alzheimer's disease. Brain Pathol 12 1 (2002) 21-35
17. Aliyev A., Chen S.G., et al. Mitochondria DNA deletions in atherosclerotic hypoperfused brain microvessels as a primary target for the development of Alzheimer's disease. J Neurol Sci 229-230 (2005) 285-292
18. Ames B.N. Mitochondrial decay, a major cause of aging, can be delayed. J Alzheimers Dis 6 2 (2004) 117-121
19. Ames B.N. Delaying the mitochondrial decay of aging. Ann N Y Acad Sci 1019 (2004) 406-411
20. Ames B.N., and Liu J. Delaying the mitochondrial decay of aging with acetylcarnitine. Ann N Y Acad Sci 1033 (2004) 108-116
21. Bates K.A., Verdile G., et al. Clearance mechanisms of Alzheimer's amyloid-beta peptide: implications for therapeutic design and diagnostic tests. Mol Psychiatry (2008) Epub ahead of print
22. Beach T.G. Physiologic origins of age-related beta-amyloid deposition. Neurodegener Dis 5 3-4 (2008) 143-145
23. Beal M.F. Aging, energy, and oxidative stress in neurodegenerative diseases. Ann Neurol 38 3 (1995) 357-366
24. Beckman K.B., and Ames B.N. The free radical theory of aging matures. Physiol Rev 78 2 (1998) 547-581
25. Beckman K.B., and Ames B.N. Mitochondrial aging: open questions. Ann N Y Acad Sci 854 (1998) 118-127
26. Beckman K.B., and Ames B.N. Endogenous oxidative damage of mtDNA. Mutat Res 424 1-2 (1999) 51-58
27. Bishop G.M., and Robinson S.R. The amyloid hypothesis: let sleeping dogmas lie?. Neurobiol Aging 23 6 (2002) 1101-1105
28. Blass J.P. Alzheimer's disease and Alzheimer's dementia: distinct but overlapping entities. Neurobiol Aging 23 6 (2002) 1077-1084
29. Bonilla E., Tanji K., et al. Mitochondrial involvement in Alzheimer's disease. Biochim Biophys Acta 1410 2 (1999) 171-182
30. Bragin V., Chemodanova M., et al. Integrated treatment approach improves cognitive function in demented and clinically depressed patients. Am J Alzheimers Dis Other Demen 20 1 (2005) 21-26
31. Breteler M.M. Vascular risk factors for Alzheimer's disease: an epidemiologic perspective. Neurobiol Aging 21 2 (2000) 153-160
32. Caspersen C., Wang N., et al. Mitochondrial Abeta: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease. FASEB J 19 14 (2005) 2040-2041
33. Castellani R., Hirai K., et al. Role of mitochondrial dysfunction in Alzheimer's disease. J Neurosci Res 70 3 (2002) 357-360
34. Cedazo-Minguez A. Apolipoprotein E and Alzheimer's disease: molecular mechanisms and therapeutic opportunities. J Cell Mol Med 11 6 (2007) 1227-1238
35. Cirillo R., Aliev G., et al. Endothelium as a therapeutical target in peripheral occlusive arterial diseases: consideration for pharmacological interventions. Pharmacol Res 29 4 (1994) 293-311
36. Cirillo R., Salvatico E., et al. Effect of cloricromene during ischemia and reperfusion of rabbit hindlimb: evidence for an involvement of leukocytes in reperfusion-mediated tissue and vascular injury. J Cardiovasc Pharmacol 20 6 (1992) 969-975
37. Coria F., Castano E., et al. Isolation and characterization of amyloid P component from Alzheimer's disease and other types of cerebral amyloidosis. Lab Invest 58 4 (1988) 454-458
38. Cormier A., Morin C., et al. In vitro effects of nicotine on mitochondrial respiration and superoxide anion generation. Brain Res 900 1 (2001) 72-79
39. Coyle J.T., and Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science 262 5134 (1993) 689-695
40. Crawford J.G. Alzheimer's disease risk factors as related to cerebral blood flow: additional evidence. Med Hypotheses 50 1 (1998) 25-36
41. Davis D.G., Schmitt F.A., et al. Alzheimer neuropathologic alterations in aged cognitively normal subjects. J Neuropathol Exp Neurol 58 4 (1999) 376-388
42. De Jong G.I., De Vos R.A., et al. Cerebrovascular hypoperfusion: a risk factor for Alzheimer's disease? Animal model and postmortem human studies. Ann N Y Acad Sci 826 (1997) 56-74
43. de la Torre J.C. Hemodynamic consequences of deformed microvessels in the brain in Alzheimer's disease. Ann N Y Acad Sci 826 (1997) 75-91
44. de la Torre J.C. Critically attained threshold of cerebral hypoperfusion: the CATCH hypothesis of Alzheimer's pathogenesis. Neurobiol Aging 21 2 (2000) 331-342
45. de la Torre J.C. Alzheimer disease as a vascular disorder: nosological evidence. Stroke 33 4 (2002) 1152-1162
46. de la Torre J.C. Alzheimer's disease: how does it start?. J Alzheimers Dis 4 6 (2002) 497-512
47. de la Torre J.C. Alzheimer's disease is a vasocognopathy: a new term to describe its nature. Neurol Res 26 5 (2004) 517-524
48. de la Torre J.C. Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol 3 3 (2004) 184-190
49. de la Torre J.C. How do heart disease and stroke become risk factors for Alzheimer's disease?. Neurol Res 28 6 (2006) 637-644
50. de la Torre J.C. Alzheimer's disease prevalence can be lowered with non-invasive testing. J Alzheimers Dis 14 3 (2008) 353-359
51. de la Torre J.C. Pathophysiology of neuronal energy crisis in Alzheimer's disease. Neurodegener Dis 5 3-4 (2008) 126-132
52. Donahue J.E., Flaherty S.L., et al. RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease. Acta Neuropathol 112 4 (2006) 405-415
53. Ellis R.J., Olichney J.M., et al. Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease: the CERAD experience, Part XV. Neurology 46 6 (1996) 1592-1596
54. Etiene D., Kraft J., et al. Cerebrovascular Pathology Contributes to the Heterogeneity of Alzheimer's Disease. J Alzheimers Dis 1 2 (1998) 119-134
55. Fiskum G., Murphy A.N., et al. Mitochondria in neurodegeneration: acute ischemia and chronic neurodegenerative diseases. J Cereb Blood Flow Metab 19 4 (1999) 351-369
56. Friston K.J., and Frackowiak R.S. Cerebral function in aging and Alzheimer's disease: the role of PET. Electroencephalogr Clin Neurophysiol Suppl 42 (1991) 355-365
57. Galle J., Bengen J., et al. Impairment of endothelium-dependent dilation in rabbit renal arteries by oxidized lipoprotein (a). Role of oxygen-derived radicals. Circulation 92 6 (1995) 1582-1589
58. Gandy S., and Heppner F.L. Alzheimer's amyloid immunotherapy: quo vadis?. Lancet Neurol 4 8 (2005) 452-453
59. Gomez-Pinilla F. Brain foods: the effects of nutrients on brain function. Nat Rev Neurosci 9 7 (2008) 568-578
60. Granger D.N., Benoit J.N., et al. Leukocyte adherence to venular endothelium during ischemia-reperfusion. Am J Physiol 257 5 Pt 1 (1989) G683-G688
61. Grant D.N. Dietary links to Alzheimer's disease. Alzheimer's Dis Rev 2 (1997) 42-55
62. Greenberg S.M., Bacskai B.J., et al. Alzheimer disease's double-edged vaccine. Nat Med 9 4 (2003) 389-390
63. Hill J.M., Bhattacharjee P.S., et al. Apolipoprotein E alleles can contribute to the pathogenesis of numerous clinical conditions including HSV-1 corneal disease. Exp Eye Res 84 5 (2007) 801-811
64. Hirai K., Aliev G., et al. Mitochondrial abnormalities in Alzheimer's disease. J Neurosci 21 9 (2001) 3017-3023
65. Hock Jr. B.J., and Lamb B.T. Transgenic mouse models of Alzheimer's disease. Trends Genet 17 10 (2001) S7-12
66. in't Veld B.A., Ruitenberg A., et al. Antihypertensive drugs and incidence of dementia: the Rotterdam Study. Neurobiol Aging 22 3 (2001) 407-412
67. Iwamoto N., Nishiyama E., et al. Distribution of amyloid deposits in the cerebral white matter of the Alzheimer's disease brain: relationship to blood vessels. Acta Neuropathol (Berl) 93 4 (1997) 334-340
68. Jagust W.J., Friedland R.P., et al. Longitudinal studies of regional cerebral metabolism in Alzheimer's disease. Neurology 38 6 (1988) 909-912
69. Jakobovits A., Lamb B.T., et al. Production of transgenic mice with yeast artificial chromosomes. Methods Mol Biol 136 (2000) 435-453
70. Jana M., Palencia C.A., et al. Fibrillar amyloid-beta peptides activate microglia via TLR2: implications for Alzheimer's disease. J Immunol 181 10 (2008) 7254-7262
71. Joachim C.L., Morris J.H., et al. Diffuse senile plaques occur commonly in the cerebellum in Alzheimer's disease. Am J Pathol 135 2 (1989) 309-319
72. Kalaria R.N. The blood-brain barrier and cerebrovascular pathology in Alzheimer's disease. Ann N Y Acad Sci 893 (1999) 113-125
73. Kalaria R.N. The role of cerebral ischemia in Alzheimer's disease. Neurobiol Aging 21 2 (2000) 321-330
74. Kalmijn S., Launer L.J., et al. Total homocysteine and cognitive decline in a community-based sample of elderly subjects: the Rotterdam Study. Am J Epidemiol 150 3 (1999) 283-289
75. Kawai M., Kalaria R.N., et al. The relationship of amyloid plaques to cerebral capillaries in Alzheimer's disease. Am J Pathol 137 6 (1990) 1435-1446
76. Kisilevsky R. Amyloid beta threads in the fabric of Alzheimer's disease. Nat Med 4 7 (1998) 772-773
77. Kulnane L.S., and Lamb B.T. Neuropathological characterization of mutant amyloid precursor protein yeast artificial chromosome transgenic mice. Neurobiol Dis 8 6 (2001) 982-992
78. Kumar A., Schapiro M.B., et al. Cerebral metabolic and cognitive studies in dementia with frontal lobe behavioral features. J Psychiatr Res 24 2 (1990) 97-109
79. Kuo Y.M., Emmerling M.R., et al. Elevated low-density lipoprotein in Alzheimer's disease correlates with brain abeta 1-42 levels. Biochem Biophys Res Commun 252 3 (1998) 711-715
80. Lee H.G., Zhu X., et al. Amyloid-beta vaccination: testing the amyloid hypothesis?: heads we win, tails you lose!. Am J Pathol 169 3 (2006) 738-739
81. Letenneur L. Risk of dementia and alcohol and wine consumption: a review of recent results. Biol Res 37 2 (2004) 189-193
82. Lindahl B., and Lindahl U. Amyloid-specific heparan sulfate from human liver and spleen. J Biol Chem 272 42 (1997) 26091-26094
83. Linseman D.A. Targeting oxidative stress for neuroprotection. Antioxid Redox Signal (2008) Epub ahead of Print
84. Liu J., Atamna H., et al. Delaying brain mitochondrial decay and aging with mitochondrial antioxidants and metabolites. Ann N Y Acad Sci 959 (2002) 133-166
85. Liu J., Head E., et al. Memory loss in old rats is associated with brain mitochondrial decay and RNA/DNA oxidation: partial reversal by feeding acetyl-L-carnitine and/or R-alpha-lipoic acid. Proc Natl Acad Sci U S A 99 4 (2002) 2356-2361
86. Liu J., Head E., et al. Comparison of the effects of L-carnitine and acetyl-L-carnitine on carnitine levels, ambulatory activity, and oxidative stress biomarkers in the brain of old rats. Ann N Y Acad Sci 1033 (2004) 117-131
87. Liu J., Killilea D.W., et al. Age-associated mitochondrial oxidative decay: improvement of carnitine acetyltransferase substrate-binding affinity and activity in brain by feeding old rats acetyl-L- carnitine and/or R-alpha-lipoic acid. Proc Natl Acad Sci U S A 99 4 (2002) 1876-1881
88. Long J., Gao F., et al. Mitochondrial decay in the brains of old rats: ameliorating effect of alpha-lipoic acid and acetyl-L: -carnitine. Neurochem Res (2008) Epub ahead of Print
89. Lovell M.A., Xie C., et al. Decreased glutathione transferase activity in brain and ventricular fluid in Alzheimer's disease. Neurology 51 6 (1998) 1562-1566
90. Luchsinger J.A., Reitz C., et al. Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology 65 4 (2005) 545-551
91. Lum H., and Roebuck K.A. Oxidant stress and endothelial cell dysfunction. Am J Physiol Cell Physiol 280 4 (2001) C719-C741
92. Mahley R.W., Weisgraber K.H., et al. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc Natl Acad Sci U S A 103 15 (2006) 5644-5651
93. Manczak M., Jung Y., et al. Time-course of mitochondrial gene expressions in mice brains: implications for mitochondrial dysfunction, oxidative damage, and cytochrome c in aging. J Neurochem 92 3 (2005) 494-504
94. Manczak M., Park B.S., et al. Differential expression of oxidative phosphorylation genes in patients with Alzheimer's disease: implications for early mitochondrial dysfunction and oxidative damage. Neuromol Med 5 2 (2004) 147-162
95. Markesbery W.R. Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med 23 1 (1997) 134-147
96. Markesbery W.R., and Carney J.M. Oxidative alterations in Alzheimer's disease. Brain Pathol 9 1 (1999) 133-146
97. Mas E., Dupuy A.M., et al. Functional Vitamin E deficiency in ApoE4 patients with Alzheimer's disease. Dement Geriatr Cogn Disord 21 3 (2006) 198-204
98. Matz R.L., Schott C., et al. Age-related endothelial dysfunction with respect to nitric oxide, endothelium-derived hyperpolarizing factor and cyclooxygenase products. Physiol Res 49 1 (2000) 11-18
99. Mecocci P., Beal M.F., et al. Mitochondrial membrane fluidity and oxidative damage to mitochondrial DNA in aged and AD human brain. Mol Chem Neuropathol 31 1 (1997) 53-64
100. Mecocci P., MacGarvey U., et al. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann Neurol 36 5 (1994) 747-751
101. Mecocci P., MacGarvey U., et al. Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain. Ann Neurol 34 4 (1993) 609-616
102. Meguro K., Blaizot X., et al. Neocortical and hippocampal glucose hypometabolism following neurotoxic lesions of the entorhinal and perirhinal cortices in the non-human primate as shown by PET. Implications for Alzheimer's disease. Brain 122 Pt 8 (1999) 1519-1531
103. Milgram N.W., Araujo J.A., et al. Acetyl-L-carnitine and alpha-lipoic acid supplementation of aged beagle dogs improves learning in two landmark discrimination tests. FASEB J 21 13 (2007) 3756-3762
104. Montine T.J., Montine K.S., et al. Central nervous system lipoproteins in Alzheimer's disease. Am J Pathol 151 6 (1997) 1571-1575
105. Moreira P.I., Siedlak S.L., et al. Autophagocytosis of mitochondria is prominent in Alzheimer disease. J Neuropathol Exp Neurol 66 6 (2007) 525-532
106. Natte R., de Boer W.I., et al. Amyloid beta precursor protein-mRNA is expressed throughout cerebral vessel walls. Brain Res 828 1-2 (1999) 179-183
107. Nicolakakis N., Aboulkassim T., et al. Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist. J Neurosci 28 37 (2008) 9287-9296
108. Nunomura A., Perry G., et al. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 60 8 (2001) 759-767
109. Nunomura A., Perry G., et al. Neuronal RNA oxidation in Alzheimer's disease and Down's syndrome. Ann N Y Acad Sci 893 (1999) 362-364
110. Nunomura A., Perry G., et al. RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. J Neurosci 19 6 (1999) 1959-1964
111. Obrenovich M.E., Smith M.A., et al. Overexpression of GRK2 in Alzheimer disease and in a chronic hypoperfusion rat model is an early marker of brain mitochondrial lesions. Neurotox Res 10 1 (2006) 43-56
112. Octave J.N. The amyloid peptide precursor in Alzheimer's disease. Acta Neurol Belg 95 4 (1995) 197-209
113. Ott A., Breteler M.M., et al. Atrial fibrillation and dementia in a population-based study. The Rotterdam Study. Stroke 28 2 (1997) 316-321
114. Ott A., Breteler M.M., et al. Prevalence of Alzheimer's disease and vascular dementia: association with education. The Rotterdam study. BMJ 310 6985 (1995) 970-973
115. Ott A., Stolk R.P., et al. Association of diabetes mellitus and dementia: the Rotterdam Study. Diabetologia 39 11 (1996) 1392-1397
116. Ott A., Stolk R.P., et al. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 53 9 (1999) 1937-1942
117. Perry G., Nunomura A., et al. Oxidative damage in Alzheimer's disease: the metabolic dimension. Int J Dev Neurosci 18 4-5 (2000) 417-421
118. Perry G., Smith M.A., et al. Cerebrovascular muscle atrophy is a feature of Alzheimer's disease. Brain Res 791 1-2 (1998) 63-66
119. Prasad M.R., Lovell M.A., et al. Regional membrane phospholipid alterations in Alzheimer's disease. Neurochem Res 23 1 (1998) 81-88
120. Prelli F., Castano E.M., et al. Different processing of Alzheimer's beta-protein precursor in the vessel wall of patients with hereditary cerebral hemorrhage with amyloidosis-Dutch type. Biochem Biophys Res Commun 151 3 (1988) 1150-1155
121. Rao A.V., and Balachandran B. Role of oxidative stress and antioxidants in neurodegenerative diseases. Nutr Neurosci 5 5 (2002) 291-309
122. Reddy P.H. Amyloid precursor protein-mediated free radicals and oxidative damage: implications for the development and progression of Alzheimer's disease. J Neurochem 96 1 (2006) 1-13
123. Reddy P.H. Mitochondrial oxidative damage in aging and Alzheimer's disease: implications for mitochondrially targeted antioxidant therapeutics. J Biomed Biotechnol 2006 3 (2006) 31372
124. Reddy P.H. Mitochondrial dysfunction in aging and Alzheimer's disease: strategies to protect neurons. Antioxid Redox Signal 9 10 (2007) 1647-1658
125. Reddy P.H., and Beal M.F. Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. Trends Mol Med 14 2 (2008) 45-53
126. Refolo L.M., Malester B., et al. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis 7 4 (2000) 321-331
127. Reid P.C., Urano Y., et al. Alzheimer's disease: cholesterol, membrane rafts, isoprenoids and statins. J Cell Mol Med 11 3 (2007) 383-392
128. Reiman E.M., Caselli R.J., et al. Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: a foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc Natl Acad Sci U S A 98 6 (2001) 3334-3339
129. Reitz C., den Heijer T., et al. Relation between smoking and risk of dementia and Alzheimer disease: the Rotterdam Study. Neurology 69 10 (2007) 998-1005
130. Rosendorff C., Beeri M.S., et al. Cardiovascular risk factors for Alzheimer's disease. Am J Geriatr Cardiol 16 3 (2007) 143-149
131. Roses A.D. On the metabolism of apolipoprotein E and the Alzheimer diseases. Exp Neurol 132 2 (1995) 149-156
132. Sala A., Aliev G.M., et al. Morphological and functional changes of coronary vasculature caused by transcellular biosynthesis of sulfidopeptide leukotrienes in isolated heart of rabbit. Blood 87 5 (1996) 1824-1832
133. Salvatico E., Aliev G.M., et al. Functional depression of isolated perfused rat heart mediated by activated leukocytes: protective effect of cloricromene. J Cardiovasc Pharmacol 24 4 (1994) 638-647
134. Sanchez-Mejia R.O., Newman J.W., et al. Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease. Nat Neurosci 11 11 (2008) 1311-1318
135. Schulz J.B., Matthews R.T., et al. The role of mitochondrial dysfunction and neuronal nitric oxide in animal models of neurodegenerative diseases. Mol Cell Biochem 174 1-2 (1997) 193-197
136. Selkoe D.J. Cell biology of the amyloid beta-protein precursor and the mechanism of Alzheimer's disease. Annu Rev Cell Biol 10 (1994) 373-403
137. Shenk, J. C., Liu, J., et al. (2009). The effect of acetyl-L-Carnitine and Lipoic acid treatment in ApoE4 mouse as a model of human Alzheimer's disease. J Neurol Sci. Epub ahead of Print.
138. Shi J., Perry G., et al. Labeling of cerebral amyloid beta deposits in vivo using intranasal basic fibroblast growth factor and serum amyloid P component in mice. J Nucl Med 43 8 (2002) 1044-1051
139. Smith J.D., and Breslow J.L. The emergence of mouse models of atherosclerosis and their relevance to clinical research. J Intern Med 242 2 (1997) 99-109
140. Smith M.A., Perry G., et al. Oxidative damage in Alzheimer's. Nature 382 6587 (1996) 120-121
141. Smith M.A., Petot G.J., et al. Commentary: diet and oxidative stress: a novel synthesis of epidemiological data on Alzheimer's disease. Alzheimer's Dis Rev 2 (1997) 58-60
142. Smith M.A., Richey Harris P.L., et al. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci 17 8 (1997) 2653-2657
143. Smith M.A., Rottkamp C.A., et al. Oxidative stress and Alzheimer's disease. Biochim Biophys Acta 1501 1 (2000) 139-144
144. Smith M.A., Rottkamp C.A., et al. Oxidative stress in Alzheimer's disease. Biochim Biophys Acta 1502 1 (2000) 139-144
145. Smith M.A., Sayre L.M., et al. Oxidative posttranslational modifications in Alzheimer disease. A possible pathogenic role in the formation of senile plaques and neurofibrillary tangles. Mol Chem Neuropathol 28 1-3 (1996) 41-48
146. Smith M.A., Sayre L.M., et al. Is Alzheimer's a disease of oxidative stress?. Alzheimer's Dis Rev 1 1 (1996) 63-67
147. Smith M.A., Taneda S., et al. Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc Natl Acad Sci U S A 91 12 (1994) 5710-5714
148. Smith M.A., Vasak M., et al. Dimethylargininase, a nitric oxide regulatory protein, in Alzheimer disease. Free Radic Biol Med 25 8 (1998) 898-902
149. Sparks D.L. Coronary artery disease, hypertension, ApoE, and cholesterol: a link to Alzheimer's disease?. Ann N Y Acad Sci 826 (1997) 128-146
150. Sparks D.L., Kuo Y.M., et al. Alterations of Alzheimer's disease in the cholesterol-fed rabbit, including vascular inflammation. Preliminary observations. Ann N Y Acad Sci 903 (2000) 335-344
151. Stewart-Lee A.L., Ferns G.A., et al. Differences in onset of impaired endothelial responses and in effects of vitamin E in the hypercholesterolemic rabbit carotid and renal arteries. J Cardiovasc Pharmacol 25 6 (1995) 906-913
152. Stewart P.A., Hayakawa K., et al. A morphometric study of the blood-brain barrier in Alzheimer's disease. Lab Invest 67 6 (1992) 734-742
153. Tagliavini F., Ghiso J., et al. Coexistence of Alzheimer's amyloid precursor protein and amyloid protein in cerebral vessel walls. Lab Invest 62 6 (1990) 761-767
154. Tapia-Arancibia L., Aliaga E., et al. New insights into brain BDNF function in normal aging and Alzheimer disease. Brain Res Rev (2008)
155. Thomas A.J., Morris C.M., et al. Distribution of amyloid beta 42 in relation to the cerebral microvasculature in an elderly cohort with Alzheimer's disease. Ann N Y Acad Sci 903 (2000) 83-88
156. van Oijen M., de Jong F.J., et al. Atherosclerosis and risk for dementia. Ann Neurol 61 5 (2007) 403-410
157. van Oijen M., Witteman J.C., et al. Fibrinogen is associated with an increased risk of Alzheimer disease and vascular dementia. Stroke 36 12 (2005) 2637-2641
158. Vinters H.V., Miller B.L., et al. Brain amyloid and Alzheimer disease. Ann Intern Med 109 1 (1988) 41-54
159. Wallace D.C. Mitochondrial DNA in aging and disease. Sci Am 277 2 (1997) 40-47
160. Wallace D.C. Mitochondrial diseases in man and mouse. Science 283 5407 (1999) 1482-1488